Skip to main content

Table 2 Comparison of SSE incidence between groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Variable

Denosumab (n = 120)

ZA(n = 122)

P - value

Total incidence of SSEs

10/120

21/122

0.04*a

SSE incidence

within 2 years

3/120

4/122

0.21a

after 2 years

7/120

17/122

0.04*a

  1. * Statistically significant values. aAnalysed using the Chi-square test. ZA: zoledronic acid; SSEs: symptomatic skeletal events